[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"invasive-fungal-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:invasive-fungal-disease":23},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,72,98,118,138],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":25,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100636697","longitudinal-cohort-study-on-invasive-fungal-disease-after-allogeneic-hematopoietic-stem-cell-transplantation-100636697",false,"NCT07569055","Longitudinal Cohort Study on Invasive Fungal Disease After Allogeneic Hematopoietic Stem Cell Transplantation","Retrospective and Prospective Longitudinal Observational Study on Invasive Fungal Disease After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\nSince January 1, 2014, patients who underwent allo-HSCT at Peking University People's Hospital and other assistance centers.\n\nExclusion Criteria:\n\n1. For any reason, such as the occurrence of severe mental disorders, the follow-up information may be unavailable;\n2. Patients deemed unsuitable for the study by the researchers.","ALL",{"count":18,"type":19},6000,"ESTIMATED","OBSERVATIONAL","Invasive fungal disease (IFD) is one of the serious complications after hematopoietic stem cell transplantation (HSCT), characterized by high incidence and high mortality. According to the data from a multi-center study in China (CAESAR 2.0), even with the extensive use of antifungal active drugs for prevention, the cumulative incidence of IFD one year after HSCT still reached 6.3%, and the IFD-related mortality rate was 48.28%. In recent years, with the improvement of transplantation techniques, the application of new antifungal drugs and the optimization of diagnostic methods, the pathogen spectrum and clinical characteristics of IFD have undergone significant changes. Compared with ten years ago, the proportion of non-Aspergillus pathogens (such as Candida and Mucophora) has significantly increased, while the proportion of Aspergillus has relatively decreased. In addition, different types of invasive mycosis (such as invasive aspergillosis and invasive fusarium) show significant differences in clinical manifestations, onset time and prognosis. However, at present, large-scale prospective cohort studies on IFD after HSCT in China are still relatively scarce, and the diagnosis and treatment norms and prevention strategies in clinical practice still need to be further optimized. This study intends to conduct a multi-center retrospective and prospective combined longitudinal cohort study to comprehensively register the basic information, diagnosis, treatment and prognosis of IFD patients after HSCT, providing evidence-based medical basis for establishing new clinical diagnosis and treatment technologies and improving the long-term survival rate of patients.",[23,24],"Invasive Fungal Disease","Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)",[26,23,27,28],"Allogeneic Hematopoietic Stem Cell Transplantation","Prediction","Prognosis","RECRUITING","2026-05-01",{"date":32,"type":33},"2026-05-06","ACTUAL",{"date":35,"type":33},"2025-03-15",{"date":37,"type":19},"2031-03-14",{"name":39,"class":40},"Peking University People's Hospital","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":41},"100635926","amphotericin-b-for-breakthrough-fungal-infections-after-triazole-prophylaxis-in-hematological-patients-100635926","NCT07559032","Amphotericin B for Breakthrough Fungal Infections After Triazole Prophylaxis in Hematological Patients","A Multicenter, Prospective, Observational Study to Evaluate the Efficacy and Safety of Amphotericin B in the Treatment of Breakthrough Invasive Fungal Disease in Hematological Patients Receiving Triazole Prophylaxis","Inclusion Criteria:\n\n1. Age ≥ 18 years old.\n2. Diagnosed with hematological diseases and receiving triazole prophylaxis.\n3. Confirmed or suspected breakthrough invasive fungal disease (IFD) according to EORTC\u002FMSG 2020 criteria.\n4. Able to understand and sign the informed consent form voluntarily.\n\nExclusion Criteria:\n\n1. Severe liver or renal dysfunction (ALT\u002FAST \\> 3×ULN, Cr \\> 2×ULN).\n2. Known allergy to amphotericin B or any component of the study drug.\n3. Pregnant or lactating women.\n4. Severe underlying diseases with expected survival \\\u003C 3 months.","18 Years",{"count":51,"type":19},15,"INTERVENTIONAL",[54],"NA","The goal of this clinical trial is to learn if amphotericin B works to treat breakthrough invasive fungal disease (IFD) in patients with hematological diseases who have received azole-based prophylaxis. It will also learn about the safety of amphotericin B in this population.\n\nThe main questions it aims to answer are:\n\n1. What is the overall response rate (complete remission + partial remission) of amphotericin B in treating breakthrough IFD after azole prophylaxis?\n2. What medical problems do participants have when taking amphotericin B?\n3. What is the 6-week (42-day) overall survival rate after starting treatment?\n\nThis is a single-arm, prospective study. Participants will:\n\n1. Receive intravenous liposomal amphotericin B (3-5 mg\u002Fkg daily) for 4-6 weeks.\n2. Undergo weekly clinical and laboratory assessments, including serum G\u002FGM tests, microbiology tests, and imaging (CT) at 2, 4, and 6 weeks.\n3. Have safety monitoring including liver and kidney function, electrolytes, and ECG.\n4. Be followed for treatment response and survival.",[23],[58,59,60,61,62],"Breakthrough fungal infection","Invasive fungal disease","Triazole prophylaxis","Amphotericin B","Hematological diseases","NOT_YET_RECRUITING","2026-04-26",{"date":66,"type":33},"2026-04-30",{"date":68,"type":19},"2026-04",{"date":70,"type":19},"2028-12-31",{"name":39,"class":40},{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":41},"100538004","immunomonitoring-of-mold-invasive-infections-100538004","NCT06285188","Immunomonitoring of Mold Invasive Infections","IMMUNOFIL","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Mold invasive fungal infection: Aspergillus, Mucorales, Fusarium, Scedosporium\n* Proven or probable according to 2019 EORTC\u002FMGS criteria modified by the adjunction of diabetes mellitus in the host criteria and Mucorales PCR in the microbiological criteria\n* Within 14 days of IFD diagnosis or\n* a refractory state defined by the 2009 MGS\u002FEORT failure criteria (clinical, radiological, or microbiological failure) of a first-line antifungal treatment leading to a change of therapy by the attending physician of the patient\n* Patients with aspergillosis or mucormycosis for whom ELISPOTs are developed: Total lymphocyte count \\> 700\u002Fmm3 on the last sample taken\n* No opposition to participate to the research\n* Affiliated or beneficiary of social security system\n\nExclusion Criteria:\n\n* Bacterial co-infection in the last 14 days\n* Previous treatment with anti-PD1 antibodies",{"count":80,"type":19},20,"Mold invasive infections are associated with an important mortality despite optimization of the antifungal treatment. In a few case reports, immune checkpoints inhibitors, initially developed for neoplastic diseases, have shown a potential beneficial effect in such devastating infections by restoring an efficient immune response. The investigators propose a longitudinal monitoring of the adaptative immune response, notably immune checkpoint expression on T cells, during mold invasive infections to help identify the patients who could benefit from the adjunction of immunotherapy and the optimal timing of such strategy.",[23,83],"Mold Invasive Fungal Infection: Aspergillus, Mucorales, Fusarium, Scedosporium",[85,86,87,88],"Invasive fungal diseases,","adaptative immunity against filamentous fungi","immune checkpoint molecules","anti-PD1","2025-11-17",{"date":91,"type":33},"2025-11-20",{"date":93,"type":33},"2025-07-28",{"date":95,"type":19},"2027-07",{"name":97,"class":40},"Assistance Publique - Hôpitaux de Paris",{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":105,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":41},"100603381","liposomal-amphotericin-b-and-isavuconazoleposaconazole-in-br-ifd-breakthrough-invasive-fungal-disease-in-patients-with-malignant-hematological-diseases-100603381","NCT07135778","Liposomal Amphotericin B and Isavuconazole\u002FPosaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Patients With Malignant Hematological Diseases","The Efficacy and Safety of Liposomal Amphotericin B and Isavuconazole\u002FPosaconazole in the Treatment of Breakthrough Invasive Fungal Disease in Patients With Malignant Hematological Diseases After Antifungal Prophylaxis","Inclusion Criteria:\n\n* Male or female patients aged ≥ 18 years at the beginning of treatment.\n* The patient or their guardian must be able to understand and sign a written informed consent form (which must be obtained before starting any research procedure)\n* Blood based diseases, mainly AML( Acute Myeloid Leukemia), ALL(Acute Lymphoblastic Leukemia), MDS(Myelodysplastic Syndromes)\n* Breakthrough invasive fungal disease occurs after receiving antifungal prophylaxis with triazole drugs for ≥ 7 days\n* According to the latest definition of MSGERC, breakthrough IFD is defined as any IFD that occurs during exposure to antifungal drugs, including fungal infections outside the spectrum of antifungal activity\n* Proven, probable, and possible IFD in accordance with the\\\u003C The Chinese guidelines for the diagnosis and treatment of invasive fungal disease in patients with hematological disorders and cancers (the 6th revision) \\>\n\nExclusion Criteria:\n\n* Confirmed patients with allergies\u002Frapid onset severe allergic reactions\u002Fintolerance to L-AmB or isavuconazole \u002Fposaconazole\n* Serum creatinine level ≥ 2 times the upper limit of normal\n* The level of transaminase or alkaline phosphatase is ≥ 5 times the normal upper limit, and bilirubin is ≥ 3 times the normal upper limit\n* Patients who are breastfeeding\n* Pregnant patients\n* Expected life expectancy is less than 30 days\n* Patients deemed ineligible by the investigator due to medical, ethical, or logistical reasons.",{"count":106,"type":19},36,"This is a prospective, open label, controlled, single center real-world observational study. Adult (aged ≥ 18 years) patients with hematological malignancies develop breakthrough invasive fungal disease after receiving ≥ 7 days of echinocandin or triazole antifungal prophylaxis receive treatment with liposomal amphotericin B or treatment with Isavuconazole or posaconazole according to the clinical doctor's decision. It is planed to collect 36 patients receiving treatment with liposomal amphotericin B and 36 patients receiving treatment with Isavuconazole or posaconazole, and observe their efficacy and safety.",[23],"2025-08-20",{"date":111,"type":33},"2025-08-22",{"date":113,"type":33},"2025-05-19",{"date":115,"type":19},"2026-12-31",{"name":117,"class":40},"Institute of Hematology & Blood Diseases Hospital, China",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":41},"100579062","efficacy-and-safety-of-amphotericin-b-and-azoles-in-the-treatment-of-invasive-fungal-disease-100579062","NCT06819410","Efficacy and Safety of Amphotericin B and Azoles in the Treatment of Invasive Fungal Disease","A Retrospective Clinical Study on the Efficacy and Safety of Amphotericin B Compared With Azoles in the Treatment of Invasive Fungal Disease","Inclusion Criteria:\n\n* There is no age limit, gender is not limited\n* Patients with invasive fungal disease who are treated with polyene antifungals or azole antifungals should be treated for ≥ 7 days.\n\nExclusion Criteria:\n\n* Patients with incomplete data or other factors affecting the clinical outcome judgement\n* Patients who are judged by the investigator to be unsuitable to participate in this study.",{"count":126,"type":19},1000,"Efficacy and safety of amphotericin B and azoles in the treatment of invasive fungal disease",[23],"2025-02-10",{"date":131,"type":33},"2025-02-11",{"date":133,"type":33},"2021-05-01",{"date":135,"type":19},"2025-02-01",{"name":137,"class":40},"Sichuan Provincial People's Hospital",{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":146,"conditions":147,"keywords":148,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":41},"100188646","fungiscope---a-global-emerging-fungal-infection-registry-100188646","NCT01731353","FungiScope - A Global Emerging Fungal Infection Registry","FungiScope","Inclusion Criteria:\n\n* Cultural, histopathological, antigen or DNA evidence of invasive fungal infection\n\nExclusion Criteria:\n\n* Infection due to Candida spp., Cryptococcus neoformans, Pneumocystis jiroveci\n* Endemic fungal infection such as coccidioidomycosis or histoplasmosis\n* Colonisation or other non-invasive infection",{"count":126,"type":19},"The objective of this registry is to broaden the knowledge on epidemiology, diagnostic procedures and clinical course of emerging invasive fungal infections.",[23],[149,150],"invasive fungal infection","Web-based registry","2023-12-04",{"date":153,"type":33},"2023-12-05",{"date":155,"type":4},"2003-03",{"date":157,"type":19},"2026-12",{"name":159,"class":40},"University of Cologne"]